Catheter Precision (VTAK) Common Equity (2017 - 2026)

Catheter Precision (VTAK) has 10 years of Common Equity data on file, last reported at $9.2 million in Q1 2026.

• On a quarterly basis, Common Equity rose 15.68% year-over-year to $9.2 million in Q1 2026; TTM through Mar 2026 was $9.2 million, a 15.68% increase from a year earlier, with the FY2025 full-year figure at $7.1 million, down 40.0% from the prior year.
• Common Equity for Q1 2026 stood at $9.2 million, up from $7.1 million in the prior quarter.
• Over the last five years, Common Equity for VTAK reached as high as $35.9 million in Q1 2023 and fell as low as $6.5 million in Q2 2025.
• Historically, Common Equity has averaged $14.5 million across 5 years, with a median of $12.5 million in 2022.
• Across the five-year window, Common Equity surged 142.99% in 2023 and tumbled 57.27% in 2025, its largest moves.
• Year by year, Common Equity stood at $9.3 million in 2022, then surged by 128.87% to $21.2 million in 2023, then plunged by 44.52% to $11.8 million in 2024, then tumbled by 40.0% to $7.1 million in 2025, then increased by 29.81% to $9.2 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $9.2 million in Q1 2026, $7.1 million in Q4 2025, and $6.8 million in Q3 2025.